Evgen Pharma logo

EVG - Evgen Pharma Share Price

11.35p 0.5  4.6%

Last Trade - 3:38pm

Sector
Healthcare
Size
Micro Cap
Market Cap £14.9m
Enterprise Value £10.8m
Revenue £n/a
Position in Universe 1440th / 1804
Bullish
Bearish
Unlock EVG Revenue
Momentum
Relative Strength (%)
1m -23.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 March 2020, Evgen Pharma PLC revenues was not reported. Net loss increased 3% to £2.7M. Higher net loss reflects Share based compensation increase of 24% to £168K (expense), Operating expenses remaining flat at £3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -£0.03 to -£0.02.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for EVG
Graphical History

Revenue

EVG Revenue Unlock EVG Revenue

Net Income

EVG Net Income Unlock EVG Revenue

Normalised EPS

EVG Normalised EPS Unlock EVG Revenue

PE Ratio Range

EVG PE Ratio Range Unlock EVG Revenue

Dividend Yield Range

EVG Dividend Yield Range Unlock EVG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EVG EPS Forecasts Unlock EVG Revenue
Profile Summary

Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Directors
Last Annual March 31st, 2020
Last Interim March 31st, 2020
Incorporated October 2, 2014
Public Since October 21, 2015
No. of Shareholders: n/a
No. of Employees: 9
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 137,297,441
Free Float (0.0%)
Eligible for
ISAs
SIPPs
EVG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for EVG
Upcoming Events for EVG
Frequently Asked Questions for Evgen Pharma
What is the Evgen Pharma share price?

As of 3:38pm, shares in Evgen Pharma are trading at 11.35p, giving the company a market capitalisation of £14.9m. This share price information is delayed by 15 minutes.

How has the Evgen Pharma share price performed this year?

Shares in Evgen Pharma are currently trading at 11.35p and the price has moved by -27.3% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Evgen Pharma price has moved by -11.35% over the past year.

What are the analyst and broker recommendations for Evgen Pharma?

Of the analysts with advisory recommendations for Evgen Pharma, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Evgen Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Evgen Pharma next release its financial results?

Evgen Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Evgen Pharma dividend yield?

Evgen Pharma does not currently pay a dividend.

Does Evgen Pharma pay a dividend?

Evgen Pharma does not currently pay a dividend.

When does Evgen Pharma next pay dividends?

Evgen Pharma does not currently pay a dividend.

How do I buy Evgen Pharma shares?

To buy shares in Evgen Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Evgen Pharma?

Shares in Evgen Pharma are currently trading at 11.35p, giving the company a market capitalisation of £14.9m.

Where are Evgen Pharma shares listed? Where are Evgen Pharma shares listed?

Here are the trading details for Evgen Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: EVG
What kind of share is Evgen Pharma?

Based on an overall assessment of its quality, value and momentum, Evgen Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Evgen Pharma share price forecast 2020?

Shares in Evgen Pharma are currently priced at 11.35p. At that level they are trading at 0.13% discount to the analyst consensus target price of 11.36.

Analysts covering Evgen Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.023 for the next financial year.

How can I tell whether the Evgen Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evgen Pharma. Over the past six months, the relative strength of its shares against the market has been 0.198k%. At the current price of 11.35p, shares in Evgen Pharma are trading at 22.3% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Evgen Pharma PE Ratio?

We were not able to find PE ratio data for Evgen Pharma.

Who are the key directors of Evgen Pharma?

Evgen Pharma's management team is headed by:

Barry Clare - CHM
Sue Foden - NED
Alan Barge - NED
Hamina Patel - OTH
Richard Moulson - CFO
Susan Clement-Davies - NED
Who are the major shareholders of Evgen Pharma?

Here are the top five shareholders of Evgen Pharma based on the size of their shareholding:

SPARK Impact, Ltd. Investment Advisor
Percentage owned: 11.79% (16.2m shares)
Griffiths (Richard Ian) Individual Investor
Percentage owned: 10.49% (14.4m shares)
AXA Framlington UK Select Opportunities Fund Mutual Fund
Percentage owned: 8.97% (12.3m shares)
AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund
Percentage owned: 8.63% (11.8m shares)
Spreadex, Ltd. Corporation
Percentage owned: 5.66% (7.77m shares)
Similar to EVG
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.